Sensorion

Sensorion Gross Margin

The Gross Margin of Sensorion (ALSEN.PA) as of Oct 9, 2026 is 100.00 %. In the previous year, Gross Margin was 66.48 % — a change of 50.43% (higher).

Gross Margin

100.00 %

YoY

50.43%

Last updated:

Gross Margin of Sensorion is 2024 100.00 % . Gross Margin of Sensorion was 2023 66.48 % . It decreases by 50.43% higher compared to the previous year.

For Sensorion, the gross margin of 100.0% is up versus 82.3% a few years ago.

The Sensorion Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2017
80.08 EUR
Jan 1, 2018
84.44 EUR
Jan 1, 2019
87.63 EUR
Jan 1, 2020
82.35 EUR
Jan 1, 2021
87.96 EUR
Jan 1, 2022
84.38 EUR
Jan 1, 2023
66.48 EUR
Jan 1, 2024
100.00 EUR
The Sensorion Gross Margin history
YEARGross MarginYoY
100.00 %+50.43%
66.48 %-21.22%
84.38 %-4.06%
87.96 %+6.81%
82.35 %-6.03%
87.63 %+3.78%
84.44 %+5.44%
80.08 %-100.21%
-38,622.41 %+1,619.28%
-2,246.43 %-2,346.43%
100.00 %-5,733.05%
-1.78 %-277.52%
1.00 %-100.04%
-2,365.14 %—
Access this data via the Eulerpool API

Sensorion Stock analysis

What does Sensorion do? The company Sensorion SA is a French biotechnology company that specializes in developing innovative therapies for hearing and balance disorders. It was founded in 2009 and is headquartered in Montpellier. Sensorion SA's business model is based on researching and developing new drugs that can be used to treat inner ear diseases. These diseases often have severe effects on the quality of life and social interaction of those affected and represent a significant unmet medical need. Sensorion SA aims to develop innovative and effective therapies to address this need. The company specializes in two main areas: hearing disorders and balance disorders. In the field of hearing disorders, Sensorion SA focuses on developing drugs to treat sensorineural hearing loss. These disorders can be caused by various factors such as aging, noise exposure, or genetic predisposition and affect the inner ear. Sensorion SA has a promising pipeline of drugs in clinical development based on different mechanisms of action. These drugs aim to protect the inner ear and restore hearing function. In the field of balance disorders, Sensorion SA focuses on developing new drugs to treat dizziness and vestibular disorders. These disorders can be caused by factors such as aging, medications, or neurological diseases and affect the balance system in the inner ear. Sensorion SA also has a promising pipeline of drugs in clinical development in this area. Sensorion SA's products are not yet available on the market as they are still in development and undergoing clinical trials. However, the company works closely with academic and industry partners to test and validate its drugs. The development of new drugs is a lengthy and costly process that can take many years. However, Sensorion SA is confident that its therapies have the potential to improve the lives of many people. Overall, Sensorion SA has a promising business model based on the development of innovative therapies for hearing and balance disorders. The company has a promising pipeline of drugs in clinical development and works closely with partners to test and validate its products. If successful, their drugs could have a significant impact on the lives of people suffering from these diseases. Sensorion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sensorion stock

Gross Margin of Sensorion is 100.00 % in 2024.

Gross Margin of Sensorion changed from 66.48 % to 100.00 %, representing a 50.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Sensorion since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Sensorion with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

Margins — Sensorion

All Key Metrics — Sensorion